Chemodex

Tangeretin

CHF 54.00
In stock
CDX-T0415-M0055 mgCHF 54.00
CDX-T0415-M01010 mgCHF 95.00
More Information
Product Details
Synonyms 4',5,6,7,8-Pentamethoxyflavone; NSC 53909; NSC 618905; Ponkanetin; 5,6,7,8-Tetramethoxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one
Product Type Chemical
Properties
Formula C20H20O7
MW 372.37
CAS 481-53-8
RTECS DJ3102725
Source/Host Chemicals Isolated from plant source.
Purity Chemicals ≥98% (HPLC)
Appearance White to pale yellow powder.
Solubility Soluble in DMSO (10mg/ml) or DMF (10mg/ml). Sparingly soluble in ethanol (0,5 mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key ULSUXBXHSYSGDT-UHFFFAOYSA-N
Smiles O=C1C=C(C2=CC=C(OC)C=C2)OC3=C(OC)C(OC)=C(OC)C(OC)=C31
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at RT.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

Tangeritin is a polymethoxylated flavone isolated from peels of citrus fruits with antiproliferative and antioxidant properties. It inhibits signaling in cancer cells, reducing ERK phosphorylation and growth of estradiol-stimulated T47D breast cancer cells and blocking p38 MAPK, JNK, and Akt activation in interleukin-1β-stimulated human lung carcinoma A549 cells. It is described to block cell cycle progression at G1 and induce apoptosis. Shows anti-inflammatory, osteoprotective and neuroprotective effects. Tangeritin activates the pregnane X receptor, inducing MDR1 expression in human colonic LS180 cancer cells. Shown to be a Notch-1 inhibitor. Tangeretin stimulates glucose uptake via regulation of AMPK signaling pathways and has been shown to antagonize ABCB1-mediated multidrug resistance.

Product References

(1) T. Hirano, et al.; Br. J. Cancer 72, 1380 (1995) | (2) C. Chaumontet, et al.; Cancer Lett. 114, 207 (1997) | (3) S. Kawaii, et al.; Biosci. Biotechnol. Biochem. 63, 896 (1999) | (4) K.P. Datla, et al.; Neuroreport 12, 3871 (2001) | (5) M.H. Pan, et al.; Carcinogenesis 23, 1677 (2002) | (6) S. Van Slambrouck, et al.; FEBS Lett. 579, 1665 (2005) | (7) K.H. Chen, et al.; Biochem. Pharmacol. 73, 215 (2007) | (8) K.L. Morley, et al.; Cancer Lett. 251, 168 (2007) | (9) H. Satsu, et al.; J. Agricult. Food Chem. 56, 5366 (2008) | (10) M.S. Kim, et al.; Mol. Cell Endocrinol. 358, 127 (2012) | (11) Z. Shu, et al.; Int. Immunopharmacol. 19, 275 (2014) | (12) Y.Y. Lee, et al.; J. Neuroimmune Pharmacol. 11, 294 (2016) | (13) S.L. Feng, et al.; Pharmacol. Res. 110, 193 (2016) | (14) L.L. Ma, et al.; Biomed. Pharmacother. 81, 491 (2016) | (15) N. Braidy, et al.; CNS Neurol. Disord. Drug Targets 16, 387 (2017) (Review) | (16) S. Xu, et al.; Int. Immunopharmacol. 72, 402 (2019)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.